Human Metabolome Technologies, Inc.
Stock Price Chart
2026/08/21 UpdatedPrice Trend
2026/08/21 UpdatedPrice & Trading Details
2026/08/21 UpdatedPRICE
TRADING
Shareholder Composition
Updated 2026/08/01Dividend History 1Years Growth
Updated 2026/08/23| Year | Dividend | Change |
|---|---|---|
| 2026 | ¥18 | +20.0% |
| 2025 | ¥15 | 0.0% |
| 2024 | ¥15 | +50.0% |
| 2023 | ¥10 | - |
Financial Performance
2026/08/23 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥1,223M | ¥1,299M | ¥1,346M | ¥1,455M |
| Gross Profit | ¥840M | ¥860M | ¥869M | ¥922M |
| Operating Income | ¥191M | ¥211M | ¥220M | ¥250M |
| Pretax Income | ¥264M | ¥239M | ¥264M | ¥272M |
| Net Income | ¥268M | ¥286M | ¥243M | ¥256M |
| EPS | ¥45.39 | ¥48.39 | ¥41.14 | ¥43.67 |
| Operating Margin | 15.63% | 16.24% | 16.36% | 17.15% |
| Balance Sheet | ||||
| Total Assets | ¥2,069M | ¥2,291M | ¥2,603M | ¥2,375M |
| Total Equity | ¥1,487M | ¥1,772M | ¥1,947M | ¥1,909M |
| Total Liabilities | ¥582M | ¥519M | ¥657M | ¥466M |
| Cash | ¥1,505M | ¥1,657M | ¥1,789M | ¥1,562M |
| Interest-bearing Debt | ¥233M | ¥227M | ¥226M | ¥110M |
| Equity Ratio | 71.86% | 77.36% | 74.78% | 80.38% |
| D/E Ratio | 0.16 | 0.13 | 0.12 | 0.06 |
| Cash Flow | ||||
| Operating CF | ¥324M | ¥285M | ¥237M | ¥374M |
| Investing CF | -¥152M | -¥117M | -¥32M | -¥197M |
| Financing CF | ¥80M | -¥14M | -¥73M | -¥369M |
| Free CF | ¥178M | ¥168M | ¥203M | ¥225M |
| Efficiency | ||||
| ROE | 18.01% | 16.12% | 12.50% | 13.44% |
| ROA | 12.94% | 12.47% | 9.34% | 10.80% |
Latest IR Information
-
Financial Summary for FY2026 Ending June
Discloses the consolidated results and outlook for the FY2026 ending June. Includes trends in revenue, operating income, ordinary income, and net income attributable to owners of the parent, along with segment composition of sales, major cost drivers, and ongoing strategy...
Read more -
Notice regarding the status of the acquisition of treasury stock
Read more
Latest News (5 items)
Company Information
About
Human Metabolome Technologies, Inc., biotechnology company, develops metabolomics technologies and solutions for drug discovery, diagnosis, and food production in Japan. The company provides metabolome analysis services; and global profiling, targeted assays, flux analysis, and lipidomics services. It also develops biomarkers, such as Phosphorylethanolamine, a biomarker for major depressive disorder and measured in blood plasma. The company offers solutions for cancer metabolism, metabolic flux analysis, infectious diseases, basic science, preclinical and clinical, food and nutrition, and microbiome applications. Human Metabolome Technologies, Inc. has a collaboration with the Institute for Advanced Biosciences and Keio University for the development of metabolome analysis technology. The company was incorporated in 2003 and is based in Tsuruoka, Japan.
